Follow us

NH TherAguix NEWS

NH TherAguix registration document approved by Autorité des Marchés Financiers as part of planned IPO on Euronext Growth Paris

Grenoble (France), 13 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorité des marchés financiers (the “AMF”) under number I.21-048 dated 10 September 2021.

View Press Release